These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 18283386

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalská D, Pavo I.
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [Abstract] [Full Text] [Related]

  • 6. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
    Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán J, Marín F.
    Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
    [Abstract] [Full Text] [Related]

  • 7. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
    Hofstetter B, Gamsjaeger S, Varga F, Dobnig H, Stepan JJ, Petto H, Pavo I, Klaushofer K, Paschalis EP.
    Osteoporos Int; 2014 Dec; 25(12):2709-19. PubMed ID: 25037600
    [Abstract] [Full Text] [Related]

  • 11. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F, Nieves JW, Zion M, Garrett P, Neubort S, Dempster D, Lindsay R.
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [Abstract] [Full Text] [Related]

  • 15. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [Abstract] [Full Text] [Related]

  • 16. Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study.
    Yang D, Tan J, Long Y, Huang K, Han W, Wang M, Zhu S, Zeng S, Yi W.
    Aging Clin Exp Res; 2023 Mar; 35(3):531-539. PubMed ID: 36708462
    [Abstract] [Full Text] [Related]

  • 17. Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
    Ganapathy A, Nieves JW, Keaveny TM, Cosman F.
    Bone; 2023 Feb; 167():116618. PubMed ID: 36410666
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
    Le QA, Hay JW, Becker R, Wang Y.
    Ann Pharmacother; 2019 Feb; 53(2):134-143. PubMed ID: 30160186
    [Abstract] [Full Text] [Related]

  • 19. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Ballaouri I, Efstathiadou Z, Kita M, Avramidis A.
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [Abstract] [Full Text] [Related]

  • 20. Mapping Bone Changes at the Proximal Femoral Cortex of Postmenopausal Women in Response to Alendronate and Teriparatide Alone, Combined or Sequentially.
    Whitmarsh T, Treece GM, Gee AH, Poole KE.
    J Bone Miner Res; 2015 Jul; 30(7):1309-18. PubMed ID: 25639838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.